Clinical Trial Update: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing daratumumab plus Velcade, melphalan, and prednisone (DVMP) with Velcade-melphalan-prednisone (VMP) in previously untreated multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Melphalan (Melphalan)
• PREDNISONE (Prednisone)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2018-12-17